Get all your news in one place.
100's of premium titles.
One app.
Start reading
Barchart
Barchart
Wajeeh Khan

Apellis Pharma Skyrockets on Biogen Deal. Is It Too Late to Chase APLS Stock?

Apellis Pharmaceuticals (APLS) shares soared on Tuesday after Biogen (BIIB) signed a definitive agreement to acquire the biopharmaceutical firm for about $5.6 billion in cash. 

Biogen’s proposal values APLS shares at $41 each, representing a remarkable 140% premium over the price at which they closed on March 30. 

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.